Trial · NCT07517068
The Role of Acetazolamide in Mitigating Inflammation and Innate Immune Activation at High Altitude
NCT07517068, Early phase 1, Active not recruiting, University of California, Riverside
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. The Role of Acetazolamide in Mitigating Inflammation and Innate Immune Activation at High Altitude. Trials, record NCT07517068. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07517068
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- The Role of Acetazolamide in Mitigating Inflammation and Innate Immune Activation at High Altitude
- NCT number
- NCT07517068
- Status
- Active not recruiting
- Phases
- Early phase 1
- Enrollment
- 19 participants, actual
- Lead sponsor
- University of California, Riverside
- Conditions
- Hypoxemia, Acute Mountain Sickness (AMS), Inflammation, Immune Response
- Interventions
- ACETAZOLAMIDE oral capsule, Placebo Arm
- First posted
- 2026-04-08
- Last updated
- 2026-04-08
Source ClinicalTrials.gov
Registered outcomes7
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Distributions of circulating immune cell subsets. | From enrollment to 30 days following return from high altitude (approximately 1.5 months total). | Distributions of peripheral leukocyte subsets in peripheral blood will be quantified at each timepoint of exposure (sea level before ascent, days 1-3 at high altitude, and days 7 and 30 following return to sea level) and in each treatment condition (placebo and ACZ). Blood samples will be collected in the morning immediately following waking, while fasting. Cell distributions will be determined via flow cytometry. |
| Primary | Functional characteristics of peripheral immune cells. | From enrollment to 2 years after completion of sample collection. | Peripheral blood mononuclear cells (PBMCs) will be collected at each timepoint for each participant. Cells will be isolated and cryopreserved immediately following blood collection. Cells will then be transported to the laboratory at UC Riverside if collected in the field. To determine the inflammatory reactivity and sensitivity of PBMCs at each timepoint, we will culture these cells in the presence or absence of bacterial (lipopolysaccharide, LPS) and viral stimuli (R848) and measure the concentration of inflammatory cytokines (TNFa) produced by the cells as a result of this stimuli. |
| Secondary | Expression of inflammatory biomarkers in peripheral blood | From enrollment to 2 years after completion of sample collection. | Expression of cytokines and markers of vascular inflammation will be measured via ELISA or multiplex assays. Measures will be collected at each timepoint (sea level, 1-3 days at high altitude, and 7 or 30 days following return to baseline). |
| Secondary | Acute Mountain Sickness | From enrollment to 2 years following sample collection. | Acute Mountain Sickness scores and other symptoms will be evaluated at each timepoint via the 2018 Lake Louise Acute Mountain Sickness scale. The Lake Louise Acute Mountain Sickness score for an individual is the sum of the score for the four symptoms (headache, nausea/vomiting, fatigue, and dizziness/light-headedness, each scored on a 0-3 scale with 3 being the most severe). For a positive AMS definition, it is mandatory to have a headache score of at least one point, and a total score of at least three points. |
| Secondary | Hypoxic ventilatory response | From enrollment to 2 years after data collection. | Hypoxic ventilatory responses will be measured at baseline before start of treatment administration, as well as after 2 days at high altitude. Measures will be evaluated using the Duffin modified rebreathing technique (Duffin 2007). |
| Secondary | Hypercapnic ventilatory response | From enrollment to 2 years after data collection | Hypercapnic ventilatory responses will be measured at baseline before start of treatment administration, as well as after 2 days at high altitude. Measures will be evaluated using the Duffin modified rebreathing technique (Duffin 2007). |
| Secondary | Minute ventilation at rest | From enrollment to 2 years after data collection | Minute ventilation (L/min) at rest will be calculated as the product of tidal volume (L) and frequency (breaths per minute). |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07517068
GET https://conductscience.org/api/trials/v1/NCT07517068/registered